Skip to content

Randomized Controlled Study on the Detection Rate of Flat Adenomas in Colorectal Endoscopy Using AI-Assisted TXI, AI-Assisted White-Light Endoscopy, and Conventional White-Light Endoscopy

Randomized Controlled Study on the Detection Rate of Flat Adenomas in Colorectal Endoscopy Using AI-Assisted TXI, AI-Assisted White-Light Endoscopy, and Conventional White-Light Endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129102
Enrollment
Unknown
Registered
2026-07-31
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal adenoma

Interventions

AI-assisted white light colonoscopy:AI-assisted white light colonoscopy
Texture and color-enhanced imaging combined with AI-assisted colonoscopy:Texture and color-enhanced imaging combined with AI-assisted colonoscopy
white light endoscope:white light endoscope

Sponsors

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing colorectal cancer screening, or those with a positive fecal immunochemical test (FIT) result, or with symptoms/signs that require a colonoscopy, or who are being followed up with a colonoscopy after previous polyp treatment; 2.Able to provide informed consent and agree to participate; 3.Able and willing to comply with all research procedures; 4.Men or women aged between 45 and 85 years;

Exclusion criteria

Exclusion criteria: 1.Has participated in other clinical trials, has signed the informed consent form, and is currently in the follow-up period of other clinical trials. 2.Has participated in a clinical drug trial and is currently in the washout period of the experimental drug or control drug; 3.History of substance or alcohol abuse or psychological disorders in the past five years; 4.Pregnant or breastfeeding patients; 5.Known to have polyposis syndrome; 6.Patients with gastrointestinal bleeding; 7.History of inflammatory bowel disease, colorectal cancer, or colorectal surgery; 8.Patients with contraindications to a tissue biopsy; 9.Has a history of allergy to ingredients in bowel cleansers; 10.Suffering from intestinal obstruction or perforation, toxic megacolon, heart failure (class III or IV), severe cardiovascular disease, severe liver failure, or renal insufficiency, etc. 11.Researchers believe the patient is not suitable to participate in the trial;

Design outcomes

Primary

MeasureTime frame
Flat adenoma detection rate (FADR);Detection rate of right-side adenoma;

Secondary

MeasureTime frame
Average number of tiny polyps;Advanced adenoma detection rate (Advanced ADR);Adenoma Detection Rate (ADR);Average number of adenomas in the right colon;Average number of diminutive adenomas;Detection rate of diminutive adenomas;Polyp Detection Rate (PDR);Detection Rate of Tiny Polyps;Colonoscope Insertion Time;Detection rate of right-sided colon polyps;Average Number of Flat Adenomas per Patient;Success rate of cecal intubation;Average number of polyps in the right colon;Colonoscope withdrawal time;Detection rate of pedicilless serrated lesions (SDR);

Countries

China

Contacts

Public ContactXiaoBo Li

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

lxb_1969@163.com+86 21 6838 3015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026